Hervé Lebrec, PharmD, PhD, DABT has a proven record of driving strong science-based strategies for the successful progression of therapeutic candidates at all stages of development. He built strong and diverse teams to successfully develop and conduct nonclinical safety, pharmacokinetics, immunogenicity assessment of multiple types of products including small molecules, antibodies, bispecific T cell-engagers, oncolytic viruses, siRNAs, engineered T cells. 

Before focusing on providing consultant services, he was Vice President, Development Sciences at Sonoma Biotherapeutics where he oversaw nonclinical safety, Immunogenicity, pharmacokinetics and clinical pharmacology functions. Sonoma Biotherapeutics is developing engineered regulatory T cells for autoimmune diseases. 

Prior to joining Sonoma Bio, he worked in Translational Safety and Bioanalytical Sciences at Amgen Inc. where he most recently served as Executive Director of Translational Safety. He was responsible for leading a team of toxicologists and laboratory-based scientists responsible for the nonclinical safety assessment of multiple types of products (small molecules, antibodies, oncolytic viruses, siRNAs, engineered T cells) from lead optimization through post-marketing phases. In that function, Hervé also contributed to the preparation of first-in-human oncology clinical study protocols for proper integration of nonclinical data and translational safety information. Hervé also supported oncology related business development efforts through fit-for-purpose evaluations. Prior to this, Hervé was a Principal Scientist and Scientific Director in translational safety at Amgen where he served as Project Team toxicologist.

Prior to joining Amgen, Hervé served at 3M Pharmaceuticals, initially as Research Specialist, then as Pathology and Toxicology Department Manager, with a focus on the nonclinical safety assessment of small molecule Toll-like receptor agonists.

Prior to joining industry, Hervé served as Assistant Professor at the University Paris XI. Hervé received his Doctorate in Pharmacy and his PhD in Toxicology from the same University Paris XI. Hervé is a diplomate of the American Board of Toxicology.

Hervé’s research work and scientific interests have notably focused on immune-related safety issues; he co-chairs the Immunosafety Technical Committee of the non-profit HESI (Health and Environmental Sciences Institute) and is Vice President Elect of the Biotechnology Specialty Section of the Society of Toxicology.

He contributed to 60 peer-reviewed publications that can be accessed here: https://www.ncbi.nlm.nih.gov/myncbi/herve.lebrec.1/bibliography/public/